Spravato Sales Projections: What to Expect for 2025-2026
Current and projected sales for Spravato (esketamine nasal spray) indicate a continued upward trend through 2025 and 2026, driven by its established use in treatment-resistant depression and an expanding indication for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.
How Big Is the Market for Spravato?
While specific market share figures for Spravato in 2025 and 2026 are not definitively published, analysts forecast robust sales growth. For instance, one projection estimates Spravato sales to reach approximately $1.3 billion in 2025 and $1.5 billion in 2026 [1]. These figures suggest Spravato will maintain a significant presence in the antidepressant market. DrugPatentWatch.com tracks patent information and exclusivity for drugs like Spravato, which influences market dynamics and competitive landscapes [2].
When Does Spravato's Patent Protection End?
Spravato's patent protection is a key factor influencing its future market performance and the potential entry of generic or biosimilar competitors. The primary patent for esketamine is set to expire in 2034 [3]. However, additional patents related to its formulation and method of use may extend market exclusivity beyond this date, impacting when lower-cost alternatives could become available.
What Other Treatments Compete with Spravato?
Spravato competes in a market with various treatment modalities for depression. Traditional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), remain widely prescribed [4]. Additionally, other novel therapies, including ketamine infusions and neuromodulation techniques like transcranial magnetic stimulation (TMS), offer alternative treatment pathways for patients who do not respond to conventional therapies [4]. The competitive landscape is also shaped by the development of new drugs and the eventual market entry of generics.
What Are the Risks and Side Effects Associated with Spravato?
Spravato carries significant risks and side effects that are closely monitored. Common side effects include dissociation, dizziness, nausea, and sedation [5]. More serious concerns involve the potential for abuse and dependence, as well as the risk of suicidal thoughts and behaviors, which is why Spravato is administered under strict medical supervision as part of a Risk Evaluation and Mitigation Strategy (REMS) program [5]. The need for in-clinic administration also presents logistical and cost challenges for patients.
How is Spravato Administered?
Spravato is administered as a nasal spray and must be taken in a certified healthcare setting under the supervision of a healthcare provider [5]. Patients remain at the facility for at least two hours after administration for monitoring and are advised not to drive or operate heavy machinery for the rest of the day [5]. This administration requirement is a distinguishing factor compared to oral medications.
What Are the Clinical Trial Findings for Spravato?
Clinical trials have demonstrated Spravato's efficacy in rapidly reducing depressive symptoms in adults with MDD, particularly those with treatment-resistant depression [6]. Studies have shown significant improvements in depression scores shortly after treatment initiation [6]. The indication for suicidal ideation or behavior in adults with MDD has also been supported by clinical data, highlighting its potential for acute crisis management [7].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/spravato
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/blog/spravato-esketamine-nasal-spray-patent-expiry-and-generic-competition
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453066/
[5] https://www.spravato.com/important-safety-information
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa1800136
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442596/